Introduction
Cardiovascular diseases are the most life-threatening complications in patients with end-stage renal failure and their incidence is 30 times as common as that of subjects with normal renal functions 1, 2) . Left ventricular hypertrophy occurs in 75% of patients with end-stage renal failure, congestive heart failure in 40% and coronary artery sis, severity, and prognosis. It has been reported that a close relationship exists between BNP concentrations and the diagnosis, prognosis, and severity of cardiac failure 6) .
DeFilippi et al. 7) reported a significant relationship between BNP concentrations and left ventricular hypertrophy and ischemic heart disease in patients with chronic renal failure who did not receive hemodialysis. The serum level of NT-proBNP increases according to the amount of decrease in renal functions in patients with chronic renal failure, but it represents functional disturbance and hypertrophy of the left ventricle (LV) 8) . Zoccali et al. 9) suggested that the serum BNP level can be used as a valuable marker for a screening test of cardiovascular disease in patients on hemodialysis and without heart disease. Materials and Methods
Patients
This single-center cross-sectional study included pa- These measurements were converted into percentages relative to total body water, intracellular water %, and extracellular water % (ECW%) by the Lukaski formula 11) using bioimpedance analysis software.
Statistical analysis
All descriptive data were expressed as mean±SD and Table 1) .
The total volume, urea, and the creatinine level of the peritoneal dialysis fluid and urine that were drained within the 24 hour period were examined. Weekly total Kt/V was calculated according to the following method.
Weekly total Kt/V= daily Kt/V×7
Daily total Kt/V= (Kpt+Krt)/V (Kpt: peritoneal clearance, Krt: residual renal clearance, V: total volume)
Classification of patients according of the serum NT-proBNP level
Patients were divided into 3 groups: group 1 with a range of 1-1000 pg/mL (n=6), group 2 with a range of 1,001-10,000 pg/mL (n=12), and group 3 with a range of 10,001-35,000 pg/mL (n=12). In group 1, the median was 296.8 pg/mL, the minimum was 83.15 pg/mL and the maximum was 516.3 pg/mL. In group 2, the median was 4,688.1 pg/mL, the minimum was 1,585 pg/mL and the maximum was 6,579 pg/mL. In group 3, the median was 29,175.3 pg/mL, the minimum was 12,621 pg/mL and the maximum was 35,000 pg/mL. In this study, patients were not classified according to age, sex, presence of diabetes mellitus or duration of peritoneal dialysis. Group 3 showed the highest LVMI, the highest ECW%, and the lowest LVEF. However, there were no significant differences in total Kt/V, BMI, CRP, or sex among the 3 groups. The CAPD, Continuous ambulatory peritoneal dialysis; CRP, Creactive protein; BUN, Blood urea nitrogen; NT-proBNP, N -terminal pro-brain natriuretic peptide three groups were examined using the Kruskal-Wallis test (Table 2) .
Correlations between the serum NT-proBNP level and LVMI, LVEF or ECW%
There was a positive correlation between the serum NT-proBNP level and either LVMI or ECW% (r=0.854, p=0.01; and r=0.857, p=0.01, respectively) ( Fig. 1 and 3) . The serum NT-proBNP level was negatively correlated with LVEF (r= -0.835, p=0.01) (Fig. 2) . In this study, according to the criteria proposed by Framingham 12) , left ventricular hypertroply was defined as LVMI 131 g/m 2 in males and 100 g/m 2 in females, and normal LVEF (Table 2) .
Discussion
The main causes of death in patients with end-stage renal failure are cardiovascular diseases which are more prevalent in such patients than in normal subjects primarily due to excessive body water and hypertension.
Stoddard et al. 13) . When it enters blood vessels, it dissolves into inactive NT-proBNP, which consists of 76 amino acids and active BNP containing 32 amino acids.
Since NT-proBNP has a longer half life and is more stable in plasma or serum than BNP, it is more useful in clinical settings. Bay et al. 5) have reported that the serum NTproBNP level is a single factor predictive of left ventricular failure at initial evaluation. In addition, many studies have indicated that the serum NT-proBNP level can be a predictor of cardiac failure in normal subjects 4, 7) . Based on such studies, the serum NT-proBNP has been used as a valuable marker for the diagnosis, prognosis, and evaluation of treatment outcome of left ventricular failure.
Choi et al. 8) have demonstrated that although the serum NT-proBNP level increases as renal functions decreases, it shows a significant correlation with left ventricular hypertrophy and systolic/diastolic disorders and that analysis using the receiver operating characteristic curve reveals an AUC value of 0.76-0.84 which has the potential to predict and screen left ventricular hypertrophy and functional disturbance. DeFilippi et al. 7) have documented that an increase in the serum NT-proBNP level can be a predictive factor of cardiac disease in asymptomatic patients with chronic renal disease.
A previous study on the correlation between the serum NT-proBNP level and cardiac functions in patients on hemodialysis have suggested that the serum NT-proBNP level can be used as a marker for screening cardiovascular disease in patients without symptoms of cardiovascular disease 9) . Although many studies have reported that the serum NT-proBNP level has clinical implications in predicting cardiac disease in patients with chronic renal failure or those on hemodialysis, there have been few studies on the clinical implications of the serum NT-proBNP level in those on peritoneal dialysis. Thus, this study was conducted to determine the usefulness of the serum NTproBNP level in predicting cardiac disease in patients on peritoneal dialysis. As shown in this study, patients on peritoneal dialysis showed a higher NT-proBNP level than normal subjects, which may be attributed to a delay in hormone secretion due to a decrease in renal function, an increase in the volume of the left ventricle due to a longterm excess state of body water, left ventricular hypertrophy due to pressure load, and a high prevalence of ischemic heart disease and congestive heart failure 8, 14) . Since patients on peritoneal dialysis are in a persistent state of excess body water with resultant edema, left ventricular hypertrophy and congestive heat failure, the potential for left ventricular hypertrophy in such patients can be predicted by measuring ECW% which represents the state of excess body water. There have been many studies on the cor-relation between the serum NT-proBNP and body water load. Naganuma et al. 15) have demonstrated that in patients on hemodialysis, the serum NT-proBNP level is related to changes in body weight and that since the serum NT-proBNP level is lower after hemodialysis than before hemodialysis, the serum NT-proBNP is related to the state of body water. Nishikimi et al. 16) 17) reported in a bioimpedance study for the measurement of ECW% that although patients were on hemodialysis, there was no significant difference in the serum NT-proBNP level before and after hemodialysis and that there was a positive correlation between the serum NTproBNP level and the degree of retention of body water.
The reason for this may be that the heart increases in volume and stretches due to body water overload, which induces secretion of NT-proBNP from cardiac muscle cells of the atrium and ventricle 18) . In addition, it has been reported that since the serum NT-proBNP level represents the heart state before and after body water load in patients on hemodialysis, it can be used as a guideline for the prevention of cardiac disease in such patients 19) .
Lee et al. 20) have demonstrated that LVMI significantly increases and LVEF significantly decreases as the serum NT-proBNP level increases in patients on peritoneal dialysis, but that ECW% does not change. In this study, as the serum NT-proBNP level increased in patients on continuous peritoneal dialysis on an outpatient basis, LVMI significantly increased and LVEF significantly decreased, suggesting that the serum NT-proBNP level represents left ventricular hypertrophy and functional disturbance, which was consistent with the results of Lee et al. 20) In contrast to the results of Lee et al. 20) , as the 
